Verona Pharma plc (VRNA) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है London, United Kingdom. वर्तमान CEO हैं David S. Zaccardelli.
VRNA के पास है IPO तिथि 2017-04-28, 209 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Market, बाजार पूंजीकरण $72.68B.
Verona Pharma plc is a clinical-stage biopharmaceutical company headquartered in London, focused on developing innovative therapies for respiratory diseases with significant unmet medical needs. The company's lead product candidate is ensifentrine, an inhaled dual inhibitor of phosphodiesterase 3 and 4 enzymes that functions as both a bronchodilator and anti-inflammatory agent in a single compound. Ensifentrine is currently in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis, with development proceeding across three delivery formulations: nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Founded in 2005, Verona Pharma is advancing a potentially transformative approach to respiratory disease management.
